Please see the following page for frequently asked questions regarding your rheumatological condition.
If you cannot find the answer to your question or wish to discuss in more detail you can contact the nurse practitioner led telephone advice line Telephone Advice Line.
This depends on what medication you are on.
When starting Methotrexate, Sulfasalazine and Leflunomide bloods should be taken every fortnight for the first 6 weeks. If your bloods are stable it can then be reduced to monthly for 3 months, then 3-monthly thereafter.
For biologic medications, you will be advised of the monitoring requirements in writing in advance of starting your medication.
Most Rheumatology medications should be stopped if you have an infection. The exceptions to this are hydroxychloroquine and sulfasalazine, which can be continued while you have an infection.
If you decide not to start a new medication or have stopped it due to side effects, please let us know as we may need to adjust your medications and follow up appointments.
This depends on what the side effect is and how severe it is.
If you are having trouble breathing because your tongue/mouth/lips have swollen, always phone 999.
If you are having intolerable side effects from your medication, please contact us via the Advice Line.
Yes, if you have a flare of your disease which is not settling. Advice on how to manage a flare is provided here.
Please see our individual pages on conditions and drugs for more information.
This depends on the medication you are on. Most of the rheumatic conditions require good control in order to achieve the best pregnancy outcome. Please discuss this with your consultant if you are considering starting a family and see the Pregnancy section of the website for more information.
Yes, unless you have been told to stop something you are already taking.
Certain “Live” vaccines are not safe with some rheumatology drugs. Other vaccines are strongly recommended such as the COVID-19, Flu and Pneumonia vaccines. For more details on the COVID-19 vaccine, see here.